Skip to main content
. 2021 Oct 4;13(10):1617. doi: 10.3390/pharmaceutics13101617

Figure 1.

Figure 1

Summary of the most common therapeutic approaches in the Italian clinical landscape for the treatment of advanced metastatic melanoma. Between 30 and 40% of all patients receive at least one immunotherapy or at least one targeted therapy (upper panel). Among the patients treated with immunotherapeutic agents, Anti-CTLA4 (ipilimumab) monotherapy is the most administered (lower panel, left). BRAFi and MEKi combination is the most used targeted therapy (lower panel, right). Data elaborated from [92].